Korean J Hematol 2003; 38(3):
Published online September 30, 2003
© The Korean Society of Hematology
김은정, 장대영, 안진석, 이영경, 조현찬, 김유리, 김동욱
한림대학교 의과대학 내과학교실,
한림대학교 의과대학 진단검사학교실,
가톨릭대학교 의과대학 내과학교실
ST1571 is an effective agent for the patients with chronic myeloid leukemia (CML). But, complete molecular response with ST1571 is rarely reported in accelerated phase CML. Here we report a patient with accelerated phase CML who achieved complete molecular response with ST171. A 60-year old female patient visited emergency room with syncope. Her white blood cell count was 30,800/μL (basophil 23%), hemoglobin 8.9g/dL, and platelet counts 2,748,000/μL. Bone marrow was hypercellular with increase in megakaryocyte and basophils (15%). She was diagnosed as an accelerated phase CML. Seven days after stopping hydroxyurea, we used St1571 in a daily oral dose of 600mg. Generalized edema and skin rash were observed 15 days after treatment (all grade 1) and were controlled well with conservative management. Complete hematologic and cytogenetic responses were achieved after 1 month and 3 months of therapy with ST1571 respectively. Complete molecular response was simultaneously proven by conventional reverse transcriptase PCR and real-time PCR analysis. The patient still remained in complete hematologic, cytogenetic, and molecular responses for 24 months. Treatment with ST1571 was well tolerated and rapid hematologic improvement was observed. This case shows ST1571 can induce complete molecular response as well as cytogenetic response in accelerated phase CML.
Keywords Chronic myelogenous leukemia; ST1571; Molecular response
Korean J Hematol 2003; 38(3): 205-209
Published online September 30, 2003
Copyright © The Korean Society of Hematology.
김은정, 장대영, 안진석, 이영경, 조현찬, 김유리, 김동욱
한림대학교 의과대학 내과학교실,
한림대학교 의과대학 진단검사학교실,
가톨릭대학교 의과대학 내과학교실
Eun Jung Kim, Dae Young Zang, Jin Seok Ahn, Young Kyung Lee, Hyun Chan Cho, Yoo Li Kim, Dong Wook Kim
Department of Internal Medicine, Clinical Pathology, Hallym University College of Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea
Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea
ST1571 is an effective agent for the patients with chronic myeloid leukemia (CML). But, complete molecular response with ST1571 is rarely reported in accelerated phase CML. Here we report a patient with accelerated phase CML who achieved complete molecular response with ST171. A 60-year old female patient visited emergency room with syncope. Her white blood cell count was 30,800/μL (basophil 23%), hemoglobin 8.9g/dL, and platelet counts 2,748,000/μL. Bone marrow was hypercellular with increase in megakaryocyte and basophils (15%). She was diagnosed as an accelerated phase CML. Seven days after stopping hydroxyurea, we used St1571 in a daily oral dose of 600mg. Generalized edema and skin rash were observed 15 days after treatment (all grade 1) and were controlled well with conservative management. Complete hematologic and cytogenetic responses were achieved after 1 month and 3 months of therapy with ST1571 respectively. Complete molecular response was simultaneously proven by conventional reverse transcriptase PCR and real-time PCR analysis. The patient still remained in complete hematologic, cytogenetic, and molecular responses for 24 months. Treatment with ST1571 was well tolerated and rapid hematologic improvement was observed. This case shows ST1571 can induce complete molecular response as well as cytogenetic response in accelerated phase CML.
Keywords: Chronic myelogenous leukemia, ST1571, Molecular response